Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM.
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bortezomib
/ administration & dosage
Dexamethasone
/ administration & dosage
Drug Resistance, Neoplasm
/ drug effects
Female
Humans
Japan
Male
Middle Aged
Multiple Myeloma
/ drug therapy
Neoplasm Recurrence, Local
/ drug therapy
Progression-Free Survival
Thalidomide
/ administration & dosage
Treatment Outcome
Japan
OPTIMISMM
lenalidomide refractory
pomalidomide
relapsed or refractory multiple myeloma
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
07
01
2020
revised:
26
03
2020
accepted:
02
04
2020
pubmed:
17
4
2020
medline:
20
6
2020
entrez:
17
4
2020
Statut:
ppublish
Résumé
In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib and dexamethasone (PVd) significantly improved the progression-free survival (PFS) and the overall response rate (ORR) vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma. All patients were previously treated with lenalidomide (70% refractory to lenalidomide) and had received one to three prior regimens. Here we report the first efficacy and safety analysis of PVd vs Vd in Japanese patients with relapsed or refractory multiple myeloma. Seventeen patients enrolled in the OPTIMISMM trial in Japan. With a median follow-up of 14.8 months, the median PFS was 17.6 months with PVd (n = 12) vs 4.4 months with Vd (n = 5), and the ORR was 100% vs 60.0%, respectively. The safety profile was as expected for PVd. Toxicities were managed with dose reductions and interruptions, and no patients discontinued PVd due to treatment-emergent adverse events. These results are consistent with those in the overall OPTIMISMM patient population and confirm the clinical benefit of PVd in Japanese patients.
Identifiants
pubmed: 32297407
doi: 10.1111/cas.14415
pmc: PMC7293071
doi:
Substances chimiques
Thalidomide
4Z8R6ORS6L
Bortezomib
69G8BD63PP
Dexamethasone
7S5I7G3JQL
pomalidomide
D2UX06XLB5
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
2116-2122Subventions
Organisme : Celgene
Organisme : Bristol-Myers Squibb Company
Informations de copyright
© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Int J Hematol. 2019 May;109(5):509-538
pubmed: 30949913
Rinsho Ketsueki. 2018;59(10):2178-2188
pubmed: 30305524
Blood. 2014 Mar 20;123(12):1826-32
pubmed: 24421329
Blood Cancer J. 2018 May 1;8(4):41
pubmed: 29712896
Leukemia. 2012 Nov;26(11):2326-35
pubmed: 22552008
Leukemia. 2016 May;30(5):1005-17
pubmed: 26710887
Blood. 2016 Jul 28;128(4):497-503
pubmed: 27226434
Br J Haematol. 2016 Mar;172(6):889-901
pubmed: 26914976
Lancet Oncol. 2019 Jun;20(6):781-794
pubmed: 31097405
Blood Cancer J. 2017 Mar 10;7(3):e540
pubmed: 28282035
Haematologica. 2016 Apr;101(4):396-406
pubmed: 27033237
Lancet Oncol. 2013 Oct;14(11):1055-1066
pubmed: 24007748
Blood Cancer J. 2019 Mar 20;9(4):38
pubmed: 30894516
Cancer Sci. 2020 Jun;111(6):2116-2122
pubmed: 32297407
Leukemia. 2017 Nov;31(11):2443-2448
pubmed: 28620163